GBT009

Garnet BioTherapeutics, Inc. · Phase 2 active Biologic

GBT009 is an investigational therapeutic targeting an undisclosed molecular pathway in early clinical development.

At a glance

Generic name	GBT009
Sponsor	Garnet BioTherapeutics, Inc.
Modality	Biologic
Phase	Phase 2

Mechanism of action

Limited public information is available regarding GBT009's specific mechanism of action. As a Phase 2 asset from Garnet BioTherapeutics, the drug is still in early-stage clinical evaluation, and detailed mechanistic data have not been widely disclosed in the public domain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results